{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:40Z","timestamp":1792271380397,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.pharma.2022.09.006","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:15:46Z","timestamp":1663733746000},"page":"202-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nouvelles recommandations pour le d\u00e9pistage du cancer du col de l\u2019ut\u00e9rus en France"],"prefix":"10.1016","volume":"81","author":[{"given":"A.","family":"Baraquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"P\u00e9pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Floerchinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Lepiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Pr\u00e9tet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.09.006_bib0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.virol.2014.12.028","article-title":"International standardization and classification of human papillomavirus types","volume":"476","author":"Bzhalava","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.pharma.2022.09.006_bib0190","doi-asserted-by":"crossref","first-page":"pky045","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of Human Papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52\u00a0and 58","volume":"2","author":"de Sanjos\u00e9","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.pharma.2022.09.006_bib0195","first-page":"122","article-title":"Infections \u00e0 papillomavirus humains et l\u00e9sions associ\u00e9es","volume":"34","author":"Lepiller","year":"2021","journal-title":"J Pediatr Pueric"},{"key":"10.1016\/j.pharma.2022.09.006_bib0200","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5\u00a0continents: meta-analysis of 1\u00a0million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharma.2022.09.006_bib0205","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic human papillomavirus infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pharma.2022.09.006_bib0210","series-title":"R\u00e9seau fran\u00e7ais des registres de cancers Francim. Cancer du col de l\u2019ut\u00e9rus en France\u00a0: tendances de l\u2019incidence et de la mortalit\u00e9 jusqu\u2019en 2018","first-page":"410","author":"Hamers","year":"2019"},{"key":"10.1016\/j.pharma.2022.09.006_bib0215","series-title":"Genre et sexualit\u00e9. D\u2019une d\u00e9cennie \u00e0 l\u2019autre. Barom\u00e8tre sant\u00e9 2016","author":"Bajos","year":"2018"},{"key":"10.1016\/j.pharma.2022.09.006_bib0220","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncy.21521","article-title":"The Pap test and Bethesda 2014","volume":"123","author":"Nayar","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.pharma.2022.09.006_bib0225","first-page":"279","article-title":"Recommendations for the screening of uterine cervix cancer in France (July, 2010)","volume":"40","author":"Haute Autorit\u00e9 de sant\u00e9","year":"2011","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"10.1016\/j.pharma.2022.09.006_bib0230","doi-asserted-by":"crossref","DOI":"10.3390\/v10120729","article-title":"Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing","volume":"10","author":"Chrysostomou","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.pharma.2022.09.006_bib0235","first-page":"E290","article-title":"Methodologies of primary HPV testing currently applied for cervical cancer screening","volume":"10","author":"Chrysostomou","year":"2020","journal-title":"Life (Basel)"},{"key":"10.1016\/j.pharma.2022.09.006_bib0240","unstructured":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention n.d. https:\/\/www.who.int\/publications-detail-redirect\/9789240030824.(accessed August 24, 2022)."},{"key":"10.1016\/j.pharma.2022.09.006_bib0245","series-title":"D\u00e9pistage organis\u00e9 du cancer du col de l\u2019ut\u00e9rus: d\u00e9finition des indicateurs de performance et format des donn\u00e9es pour l\u2019\u00e9valuation du programme national, mise \u00e0 jour 2022\u00a0du document d\u2019octobre 2020","author":"Sant\u00e9 Publique France","year":"2022"},{"key":"10.1016\/j.pharma.2022.09.006_bib0250","series-title":"\u00c9valuation de la recherche des papillomavirus humains (HPV) en d\u00e9pistage primaire des l\u00e9sions pr\u00e9canc\u00e9reuses et canc\u00e9reuses du col de l\u2019ut\u00e9rus et de la place du double immuno-marquage p16\/Ki67.","author":"Haute Autorit\u00e9 de sant\u00e9 HAS","year":"2019"},{"key":"10.1016\/j.pharma.2022.09.006_bib0255","first-page":"CD008587","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","volume":"8","author":"Koliopoulos","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharma.2022.09.006_bib0260","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2020.03.033","article-title":"Commercially available molecular tests for human papillomaviruses: a global overview","volume":"26","author":"Poljak","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pharma.2022.09.006_bib0265","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30\u00a0years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharma.2022.09.006_bib0270","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcv.2015.09.014","article-title":"VALGENT: a protocol for clinical validation of human papillomavirus assays","volume":"76","author":"Arbyn","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1016\/j.pharma.2022.09.006_bib0275","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","article-title":"2020\u00a0list of human papillomavirus assays suitable for primary cervical cancer screening","volume":"27","author":"Arbyn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pharma.2022.09.006_bib0280","series-title":"R\u00e9f\u00e9rentiel national\u00a0\u2013\u00a0d\u00e9pistage du cancer du col de l\u2019ut\u00e9rus\u00a0\u2013\u00a0cadre et modalit\u00e9s de recours aux autopr\u00e9l\u00e8vements vaginaux","author":"Institut national du cancer","year":"2022"},{"key":"10.1016\/j.pharma.2022.09.006_bib0285","doi-asserted-by":"crossref","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2022.09.006_bib0290","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pharma.2022.09.006_bib0295","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/jnci\/djt235","article-title":"Screening for cervical cancer precursors with p16\/Ki-67\u00a0dual-stained cytology: results of the PALMS study","volume":"105","author":"Ikenberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharma.2022.09.006_bib0300","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1055-9965.EPI-09-0328","article-title":"Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer","volume":"18","author":"Balasubramanian","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.pharma.2022.09.006_bib0305","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jamaoncol.2018.4270","article-title":"Five-year risk of cervical precancer following p16\/Ki-67\u00a0dual-stain triage of HPV-positive women","volume":"5","author":"Clarke","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pharma.2022.09.006_bib0310","doi-asserted-by":"crossref","first-page":"djv257","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67\u00a0dual stain cytology for detection of cervical precancer in HPV-positive women","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharma.2022.09.006_bib0315","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ijc.33812","article-title":"Clinical validation of p16\/Ki-67\u00a0dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial","volume":"150","author":"Wright","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharma.2022.09.006_bib0320","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41416-019-0593-4","article-title":"Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis","volume":"121","author":"Kelly","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharma.2022.09.006_bib0325","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ebiom.2019.10.053","article-title":"The use of human papillomavirus DNA methylation in cervical intraepithelial neoplasia: a systematic review and meta-analysis","volume":"50","author":"Bowden","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharma.2022.09.006_bib0330","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ijc.30008","article-title":"Validation of a DNA methylation HPV triage classifier in a screening sample","volume":"138","author":"Lorincz","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharma.2022.09.006_bib0335","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789\u00a0HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharma.2022.09.006_bib0340","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JCM.01212-08","article-title":"Analysis of human papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV16-infected women with high-grade lesions or cervical carcinoma","volume":"46","author":"Saunier","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pharma.2022.09.006_bib0345","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/cancers13164149","article-title":"HPV16\u00a0load is a potential biomarker to predict risk of high-grade cervical lesions in high-risk HPV-infected women: a large longitudinal french hospital-based cohort study","volume":"13","author":"Baumann","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.pharma.2022.09.006_bib0350","doi-asserted-by":"crossref","first-page":"dju241","DOI":"10.1093\/jnci\/dju241","article-title":"MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women","volume":"106","author":"Tian","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharma.2022.09.006_bib0355","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000371760","article-title":"Can genomic amplification of human telomerase gene and C-MYC in liquid-based cytological specimens be used as a method for opportunistic cervical cancer screening?","volume":"80","author":"Gao","year":"2015","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.pharma.2022.09.006_bib0180","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw100","article-title":"HPV16\u00a0sublineage associations with histology-specific cancer risk using HPV whole-genome sequences in 3200\u00a0women","volume":"108","author":"Mirabello","year":"2016","journal-title":"J Natl Cancer Inst"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:12Z","timestamp":1757720232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0003450922001201"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.09.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles recommandations pour le d\u00e9pistage du cancer du col de l\u2019ut\u00e9rus en France","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}